News

InCarda Presents Phase 2 Safety and Efficacy Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Heart Rhythm Society Conference in San Francisco

[caption id="attachment_23373" align="aligncenter" width="800"] Dr. Chris Dufton, SVP of Clinical Development, answering questions about INSTANT P2 at HRS 2022 in San Francisco.[/caption] Phase 2 INSTANT study results demonstrate rapid and reproducible restoration of normal heart rhythm with symptom resolution and a predictable and favorable safety profile...

InCarda Therapeutics Announces Publication of Phase 2 Data Demonstrating Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm Is Safe and Effective

The original article titled “Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm” published in the peer-reviewed journal, Circulation: Arrhythmia and Electrophysiology San Francisco, California, March 15, 2022 – InCarda Therapeutics, Inc. (InCarda) announces that...

InCarda Presents Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Atrial Fibrillation Symposium in New York

Phase 2 INSTANT study results demonstrate rapid restoration of normal heart rhythm with a predictable and favorable safety profile for orally inhaled flecainide.   [caption id="attachment_23370" align="aligncenter" width="800"] Meisa Propst, VP of Clinical Operations at InCarda, presented the P2 INSTANT Safety Analysis Poster at the 2022 AF...

InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team

Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in Atrial Fibrillation in Q3 2021; Data Expected 2H 2022 Appointment of Angela Wang as CFO Strengthens...